---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-415559"
form_type: "8-K"
ticker: "CRBU"
cik: "0001619856"
company_name: "Caribou Biosciences, Inc."
filed_at: "2026-10-06T20:07:10+00:00"
generated_at: "2026-10-12T16:20:51.191016+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Caribou Biosciences halts vispa-cel and CB-011 CAR-T programs, cuts workforce, explores strategic alternatives

## Summary
- Board approved restructuring on Oct 2, 2026 with estimated charges of $15M-$19M: $10M-$11M severance/benefits and $5M-$8M to wind down the ANTLER and CaMMouflage phase 1 trials.
- Majority of affected employees expected to depart in Q4 2026; Board formed a Transaction Committee and engaged Wedbush Securities Inc. as exclusive financial advisor for the strategic review.
- CFO Sriram Ryali's employment terminates upon execution of a binding definitive agreement for a strategic alternative; treated as termination without cause with severance.
- Cash, cash equivalents and marketable securities totaled $113.8M as of June 30, 2026; no timeline set for completing the strategic alternatives review.
- Discontinued programs: vispa-cel for r/r B cell non-Hodgkin lymphoma (pivotal trial-ready, FDA-aligned phase 3 design, RMAT/Fast Track/Orphan designations) and CB-011 for r/r multiple myeloma.

## SEC filing metadata
- accession: 0001193125-26-415559
- form_type: 8-K
- ticker: CRBU
- cik: 0001619856
- company_name: Caribou Biosciences, Inc.
- filed_at: 2026-10-06T20:07:10+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.05, 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1619856/000119312526415559/0001193125-26-415559-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1619856/000119312526415559/d235175d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-415559
- JSON: https://secwatch.observer/filing/0001193125-26-415559.json
- Plain text: https://secwatch.observer/filing/0001193125-26-415559.txt

## Key facts
- Executive change
  Sriram Ryali departed as Chief Financial Officer at Caribou Biosciences, Inc..
  - Action: terminate
  - Role: Chief Financial Officer
  source text: The employment of Sriram Ryali, the Company’s Chief Financial Officer, will terminate on the date the Company executes a binding definitive agreement for a strategic alternative, and such termination would be treated as a termination “without cause” under the Employment Agreement, dated January 2, 2025, between the Company and Mr. Ryali (the “Ryali Employment Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1619856/000119312526415559/0001193125-26-415559-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.